Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ribavirin Interferon alfa

Sarrazin, C., Berg, T., Welch, V., et al. (2005) GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. J. Hepatol. 43,388-393. [Pg.101]

Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002 35(l) 89-92. [Pg.1826]

Type I diabetes mellitus and thyroid disease reportedly develop in 0.08-2.6% and 10-15% of patients treated with combined interferon alfa- -ribavirin for chronic hepatitis C but rarely coexist however, both conditions have been reported in a 33-year-old woman [50 ]. In another case, a 55-year-old woman developed type 1 diabetes and had a recurrence of Graves disease during treatment with peginterferon alfa -I- ribavirin for chronic hepatitis C [51 ]. There were serum anti-glutamic acid decarboxylase antibodies and the authors suggested that she had autoimmune polyglandular syndrome type III. [Pg.454]

A 56-year-old black woman developed with bilateral orbital swelling in the region of the lacrimal glands after taking interferon-alfa + ribavirin for 4 months for occupationally acquired hepatitis C infection [43 ]. Bilateral lacrimal gland biopsies showed granulomatous inflammation. All other tests were negative for sarcoidosis. [Pg.774]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

BriUanti S, Garson J, FoU M, Whitby K, Deaville R, Masci C, MigUoU M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107 812-817... [Pg.231]

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, Hepatitis Interventional Xherapy Group. N Engl J Med 339(21) 1485-1492... [Pg.344]

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. [Pg.356]

The safety and efficacy of ribavirin capsules or oral solution with interferons other than interferon alfa-2b or peginterferon alfa-2b products have not been established. [Pg.1772]

Ribavirin capsules/oral solution/interferon alfa-2b Patients with autoimmune... [Pg.1778]

Capsules/Tablets/Oral solution - Ribavirin monotherapy is not effective for the treatment of chronic HCV infection. The safety and efficacy of ribavirin capsules and oral solution have only been established when used together with interferon alfa-2b, recombinant as interferon alfa-2b/ribavirin capsule combination therapy or with peginterferon alfa-2b injection. [Pg.1778]

Capsules/Tablets/Oral solution-There are significant adverse events caused by ribavirin capsules/interferon alfa-2b or peginterferon alfa-2b therapy, and ribavirin tablets/peginterferon alfa-2a therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. [Pg.1778]

Pancreatitis Suspend ribavirin, interferon alfa-2b, peginterferon alfa-2b, or peginterferon alfa-2a therapy in patients with signs and symptoms of pancreatitis and discontinue in patients with confirmed pancreatitis. [Pg.1779]

Chronic hepatitis C Alone or in combination with ribavirin tablets for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been treated previously with interferon alfa. [Pg.1981]

Immunogenicity Nine percent of patients treated with peginterferon alfa-2a with or without ribavirin tablets developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. The clinical and pathological significance of the appearance of serum neutralizing antibodies is unknown. [Pg.1991]

Immunogenicity Approximately 2% of patients receiving peginterferon alfa-2b or interferon alfa-2b with or without ribavirin capsules developed low-titer (160 or less) neutralizing antibodies to peginterferon alfa-2b or interferon alfa-2b. [Pg.2000]

Peg Interferon Alfa 2b (PEG-Intron) [Antiviral/ Immunomodulator] WARNING Can cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disord s. Monitor pts closely Uses Rx Hep C Action Immune modulation Dose 1 mcg/kg/wk SQ 1.5 mcg/kg/wk combined w/ ribavirin Caution [C, X if used w/ ribavirin /-] w/ Hx psychiatric Contra Autoimmune H, decompensated Uvct Dz, hemoglobinopathy Disp Vials 50, 80, 120, 150 mcg/0.5 mL Redipen 50, 80,120,150 mcg/5 mL reconstitute w/ 0.7 mL w/ sterile water SE D ession, insomnia, suicidal behavior, GI upset, neutropenia, thrombocytopenia, alopecia, pruritus Interactions t Myelosuppression W/ antineoplastics t effects OF doxorubicin, theophylline t neurotox W7 vinblastine EMS See Peg Interf on Alfa-2a may cause flu-like Sxs... [Pg.250]

Rx Interferon alfa-2b with ribavirin (Rebetron Combination Therapy) Chemical Class Recombinant interferon... [Pg.631]

Rebetron Combination Therapy (kit containing interferon alfa-2b inj plus ribavirin capsules) more effective than interferon alfa-2b monotherapyfor chronic hepatitis C infection... [Pg.633]

Chronic hepatitis C PO (capsule or oral solution in combination with interferon alfa-2b) 1,000-1,200 mg/day in 2 divided doses. PO (capsules in combination with peginterferon alfa-2b) 800 mg/day in 2 divided doses. PO (tablets in combination with peginterferon alfa-2b) 800-1,200 mg/day in 2 divided doses. Ribavirin with peginterferon alfa-2b requires individualized dosing. [Pg.1084]

Hepatitis C therapy interferon alfa-2b/ribavirin peginterferon-2b peginterferon alfa-2b/ribavirin... [Pg.625]

McHutchison, J.G., S. Gordon, E.R. Schiff, et al.. Interferon alfa-2b montherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C results of a US. multicenter randomized controlled study. New Engl J Med, 1998. 339 1485-92. [Pg.185]

Fried, M.W., M.L. Shiffman, R.K. Reddy, et al., Pegylated interferon alfa-2a in combination with ribavirin efficacy and safety results... [Pg.185]

Manns, M.P., J.G. McHntchison, S. Gordon, et al., Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C a randomized trial. Lancet, 2001. 358 958-65. [Pg.185]

Poynard, T., J. McHutchison, G.L. Davis, Esteban, R. Mur, Z. Goodman, P. Bedossa, and J. Albrecht, Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology, 2000.32 1131-7. [Pg.185]

F. Role in therapy According to Micromedex, current agents of choice in the treatment of chronic hepatitis C are interferon alfa-2a, alfa-2b,alfacon-l, peginterferon alfa-2b, or alfa-2b plus ribavirin. Efficacy of these interferons is similar, although response rates have been higher with the addition of oral ribavirin. In a... [Pg.206]

See other pages where Ribavirin Interferon alfa is mentioned: [Pg.1067]    [Pg.675]    [Pg.455]    [Pg.1067]    [Pg.675]    [Pg.455]    [Pg.234]    [Pg.235]    [Pg.235]    [Pg.237]    [Pg.237]    [Pg.238]    [Pg.240]    [Pg.240]    [Pg.341]    [Pg.344]    [Pg.356]    [Pg.227]    [Pg.1774]    [Pg.1774]    [Pg.1778]    [Pg.1990]    [Pg.1991]    [Pg.249]   
See also in sourсe #XX -- [ Pg.780 ]



SEARCH



Interferon + ribavirin

Interferon alfa

© 2024 chempedia.info